

Agios TIBSOVO® Limited Distribution Plan

This notice provides information for eligible 340B covered entities about how to acquire TIBSOVO® (ivosidenib). Agios offers the 340B price to all eligible covered entities that satisfy the patient care requirements below.

TIBSOVO is an orphan oral oncologic therapy. Specifically, TIBSOVO is an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Agios has developed a limited distribution plan designed to ensure that patients being treated with TIBSOVO receive the best possible care. All pharmacies – 340B and otherwise – are subject to this plan equally.

TIBSOVO is available for purchase by healthcare facilities that maintain in-house pharmacies that are equipped to meet the specific needs of patients with acute myeloid leukemia, including, for example, by maintaining an on-site prescribing oncologist and staff to monitor patients on cancer medications. If your facility meets these criteria, you may purchase TIBSOVO at the 340B price from the following specialty distributor partners: McKesson Plasma and Biologics, ASD Healthcare, Oncology Supply and Cardinal Health. Contact information for these specialty distributors can be found at www.myagios.com.

Agios also supplies TIBSOVO through two specialty pharmacies with deep oncology experience and with a focus on providing oncology-specific care and patient support: Diplomat Pharmacy, Inc. and Biologics, Inc. If your pharmacy does not meet the cancer care criteria, or you choose not to order through our specialty distributor partners, your patients can still access TIBSOVO through one of these specialty pharmacies. The specialty pharmacy will fill prescriptions from your institution and ship TIBSOVO directly to your patients' homes. Contact information for these specialty pharmacies can be found at www.myagios.com.

Agios is committed to both patient well-being and compliance with the rules of the 340B program. If you have any questions about this plan, or any difficulty obtaining TIBSOVO for your patients, please contact Agios at 1-617-649-8600.